Recent legal developments are having a real and immediate impact on how the pharmaceutical industry conducts business. Court decisions denying injunctive relief to patentees and allowing early generic entry, raids by the European Commission on pharmaceuticals to investigate allegedly anti-competitive behavior, the Federal Trade Commission’s skepticism regarding the settlement of patent suits, and civil antitrust suits alleging bad faith enforcement of patents may all have an effect on the traditional incentives to innovate.
You are invited to a day-long Pharma Industry Forum sponsored by the Rutgers School of Law - Newark and Sidley. The Forum will explore recent legal developments in an interactive series of panels including federal judges and representatives of the Federal Trade Commission and the European Commission. The event will include light breakfast, lunch and a reception following the program.
The Forum will explore the following issues:
- A panel of federal judges will explore the latest developments and pressing issues facing litigants involved in pharmaceutical patent litigation.
- A panel with representatives of the Federal Trade Commission and the European Commission will discuss antitrust concerns and current enforcement priorities.
- A panel of in-house counsel will provide the “company perspective,” discussing the most challenging new issues, including decisions with the greatest impact on their practices.
For more information, please contact Gary.Gerard@sidley.com.
The Forum will feature roundtable and interactive discussions including audience participation. An agenda will be sent prior to the event. CLE credit is pending.